Meiragtx Holdings Plc's Revenue in the fiscal year 2025 $ 81.39 millions
Meiragtx Holdings Plc's Revenue in the fiscal year 2024 $ 33.28 millions
Meiragtx Holdings Plc's Revenue in the fiscal year 2023 $ 14.02 millions
Meiragtx Holdings Plc's Revenue in the fiscal year 2021 $ 15.92 millions
Meiragtx Holdings Plc's Revenue in the fiscal year 2020 $ 15.56 millions
MGTX Revenue second quarter 2026 Y/Y Growth Comment
Meiragtx Holdings Plc achieved in the second quarter 2026, above Company average Revenue surge of 8610.95% year on year, to $ 321.43 millions.
Looking into second quarter 2026 results within Biotechnology & Pharmaceuticals industry 36 other companies have achieved higher Revenue growth. While Meiragtx Holdings Plc' s Revenue doubling of 8610.95% ranks overall at the positon no. 2186 in the second quarter 2026.
MGTX Revenue ( Y/Y Growth %)
2026
2025
2024
2023
4th Quarter
December
-
252.31 %
948.53 %
-
3rd Quarter
September
-
-96.24 %
113.92 %
5.81 %
2nd Quarter
June
8610.95 %
1217.86 %
-92.09 %
-67.1 %
1st Quarter
March
-84.97 %
175.71 %
-78.98 %
-40.85 %
FY
-
144.56 %
137.54 %
-
Financial Statements
Meiragtx Holdings Plc's second quarter 2026 Revenue
Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026
Meiragtx Holdings Plc's Q/Q Revenue Growth
Revenue Q/Q Growth Statistics
High
Average
Low
109604.44 %
4888.46 %
-99.61 %
(Jun 30 2026)
MGTX's II. Quarter Q/Q Revenue Comment
Meiragtx Holdings Plc achieved in the II. Quarter 2026 above company average sequential Revenue doubling of 110739.31%, to $ 321.43 millions, from $0.29 millions in the first quarter. MGTX is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.
Within Biotechnology & Pharmaceuticals industry Meiragtx Holdings Plc achieved highest sequential Revenue growth. While Meiragtx Holdings Plc's Revenue growth quarter on quarter, overall rank is 2.
Meiragtx Holdings Plc achieved in the II. Quarter 2026 above company average sequential Revenue doubling of 110739.31%, to $ 321.43 millions, from $0.29 millions in the first quarter. MGTX is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.
Within Biotechnology & Pharmaceuticals industry Meiragtx Holdings Plc achieved highest sequential Revenue growth. While Meiragtx Holdings Plc's Revenue growth quarter on quarter, overall rank is 2.
Meiragtx Holdings Plc's 12 Months Revenue Growth Year on Year
Revenue TTM Growth
12 Months Ending (Jun 30 2026)
12 Months Ending (Mar 31 2026)
12 Months Ending (Dec 31 2025)
12 Months Ending (Sep 30 2025)
12 Months Ending (Jun 30 2025)
Cumulative Revenue 12 Months Ending
$ 397.50
$ 79.76
$ 81.39
$ 27.42
$ 37.92
Y / Y Revenue Growth (TTM)
948.35 %
131.13 %
144.57 %
96.83 %
366.84 %
Year on Year Revenue Growth Overall
Ranking
# 84
# 69
# 87
# 75
# 362
Seqeuential Revenue Change (TTM)
398.38 %
-2.01 %
196.86 %
-27.69 %
9.88 %
Seq. Revenue Growth (TTM) Overall
Ranking
# 2186
# 1822
# 86
# 123
# 2698
Cumulative Revenue growth Comment
Meiragtx Holdings Plc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 948.35% year on year, to $ 398 millions if the fiscal year would have ended in Jun 30 2026. Meiragtx Holdings Plc's trailing twelve months Revenue growth was higher than company's average 66.12% and higher than 131.13% growth in Mar 31 2026. But from twelve months ended Mar 31 2026 rise was beneth at 398.38 % from $79.76 millions achieved in the period from Mar 31 2026 to Jun 30 2025. Still this was evidence of convincing trend, while the usual Q/Q TTM gain stands at 66.12%. The momentum is even more impressive from twelve months ended Mar 31 2026 exhibited at 398.38 % increase from $79.76 millions in the period from Mar 31 2026 to Jun 30 2025.
Within the Healthcare sector 27 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 69 to 84.
Meiragtx Holdings Plc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 948.35% year on year, to $ 398 millions if the fiscal year would have ended in Jun 30 2026. Meiragtx Holdings Plc's trailing twelve months Revenue growth was higher than company's average 66.12% and higher than 131.13% growth in Mar 31 2026. But from twelve months ended Mar 31 2026 rise was beneth at 398.38 % from $79.76 millions achieved in the period from Mar 31 2026 to Jun 30 2025. Still this was evidence of convincing trend, while the usual Q/Q TTM gain stands at 66.12%. The momentum is even more impressive from twelve months ended Mar 31 2026 exhibited at 398.38 % increase from $79.76 millions in the period from Mar 31 2026 to Jun 30 2025.
Within the Healthcare sector 27 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 69 to 84.
About Meiragtx Holdings Plc Revenue Growth Rates (MGTX), Current and Historic Growth - CSIMarket Analysis
How we calculate this
This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years).
Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
8,608.59%